|
1
|
DeSantis C, Ma J, Bryan L and Jemal A:
Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jovanovic J, Rønneberg JA, Tost J and
Kristensen V: The epigenetics of breast cancer. Mol Oncol.
4:242–254. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Calmon MF, Jeschke J, Zhang W, Dhir M,
Siebenkäs C, Herrera A, Tsai HC, O'Hagan HM, Pappou EP, Hooker CM,
et al: Epigenetic silencing of neurofilament genes promotes an
aggressive phenotype in breast cancer. Epigenetics. 10:622–632.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Winter J, Jung S, Keller S, Gregory RI and
Diederichs S: Many roads to maturity: MicroRNA biogenesis pathways
and their regulation. Nat Cell Biol. 11:228–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Manikandan J, Aarthi JJ, Kumar SD and
Pushparaj PN: Oncomirs: The potential role of non-coding microRNAs
in understanding cancer. Bioinformation. 2:330–334. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu M, Yang R, Urrehman U, Ye C, Yan X,
Cui S, Hong Y, Gu Y, Liu Y, Zhao C, et al: MiR-19b suppresses PTPRG
to promote breast tumorigenesis. Oncotarget. 7:64100–64108. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mutlu M, Saatci Ö, Ansari SA, Yurdusev E,
Shehwana H, Konu Ö, Raza U and Şahin Ö: miR-564 acts as a dual
inhibitor of PI3 K and MAPK signaling networks and inhibits
proliferation and invasion in breast cancer. Sci Rep. 6:325412016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang Z, Chen D, Nie J, Zhou S, Wang J,
Tang Q and Yang X: MicroRNA-143 targets CD44 to inhibit breast
cancer progression and stem cell-like properties. Mol Med Rep.
13:5193–5199. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bertoli G, Cava C and Castiglioni I:
MicroRNAs: New biomarkers for diagnosis, prognosis, therapy
prediction and therapeutic tools for breast cancer. Theranostics.
5:1122–1143. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Houtkooper RH, Pirinen E and Auwerx J:
Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol
Cell Biol. 13:225–238. 2012.PubMed/NCBI
|
|
12
|
Bosch-Presegué L and Vaquero A: The dual
role of sirtuins in cancer. Genes Cancer. 2:648–662. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
North BJ and Verdin E: Sirtuins:
Sir2-related NAD-dependent protein deacetylases. Genome Biol.
5:2242004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Matsushima S and Sadoshima J: The role of
sirtuins in cardiac disease. Am J Physiol Heart Circ Physiol.
309:H1375–H1389. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Michishita E, Park JY, Burneskis JM,
Barrett JC and Horikawa I: Evolutionarily conserved and
nonconserved cellular localizations and functions of human SIRT
proteins. Mol Biol Cell. 16:4623–4635. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Meng X, Tan J, Li M, Song S, Miao Y and
Zhang Q: Sirt1: Role under the condition of ischemia/hypoxia. Cell
Mol Neurobiol. 37:17–28. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Donmez G and Outeiro TF: SIRT1 and SIRT2:
Emerging targets in neurodegeneration. EMBO Mol Med. 5:344–352.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lombard DB, Alt FW, Cheng HL, Bunkenborg
J, Streeper RS, Mostoslavsky R, Kim J, Yancopoulos G, Valenzuela D,
Murphy A, et al: Mammalian Sir2 homolog SIRT3 regulates global
mitochondrial lysine acetylation. Mol Cell Biol. 27:8807–8814.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Onyango P, Celic I, McCaffery JM, Boeke JD
and Feinberg AP: SIRT3, a human SIR2 homologue, is an NAD-dependent
deacetylase localized to mitochondria. Proc Natl Acad Sci USA.
99:pp. 13653–13658. 2002; View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nakagawa T, Lomb DJ, Haigis MC and
Guarente L: SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and
regulates the urea cycle. Cell. 137:560–570. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Haigis MC, Mostoslavsky R, Haigis KM,
Fahie K, Christodoulou DC, Murphy AJ, Valenzuela DM, Yancopoulos
GD, Karow M, Blander G, et al: SIRT4 inhibits glutamate
dehydrogenase and opposes the effects of calorie restriction in
pancreatic beta cells. Cell. 126:941–954. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mao Z, Hine C, Tian X, Van Meter M, Au M,
Vaidya A, Seluanov A and Gorbunova V: SIRT6 promotes DNA repair
under stress by activating PARP1. Science. 332:1443–1446. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
McCord RA, Michishita E, Hong T, Berber E,
Boxer LD, Kusumoto R, Guan S, Shi X, Gozani O, Burlingame AL, et
al: SIRT6 stabilizes DNA-dependent protein kinase at chromatin for
DNA double-strand break repair. Aging (Albany NY). 1:109–121. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kiran S, Anwar T, Kiran M and Ramakrishna
G: Sirtuin 7 in cell proliferation, stress and disease: Rise of the
Seventh Sirtuin! Cell Signal. 27:1–682. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ford E, Voit R, Liszt G, Magin C, Grummt I
and Guarente L: Mammalian Sir2 homolog SIRT7 is an activator of RNA
polymerase I transcription. Genes Dev. 20:1075–1080. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim JK, Noh JH, Jung KH, Eun JW, Bae HJ,
Kim MG, Chang YG, Shen Q, Park WS, Lee JY, et al: Sirtuin7
oncogenic potential in human hepatocellular carcinoma and its
regulation by the tumor suppressors MiR-125a-5p and MiR-125b.
Hepatology. 57:1055–1067. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen S, Seiler J, Santiago-Reichelt M,
Felbel K, Grummt I and Voit R: Repression of RNA polymerase I upon
stress is caused by inhibition of RNA-dependent deacetylation of
PAF53 by SIRT7. Mol Cell. 52:303–313. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hubbi ME, Hu H, Kshitiz, Gilkes DM and
Semenza GL: Sirtuin-7 inhibits the activity of hypoxia-inducible
factors. J Biol Chem. 288:20768–20775. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shin J, He M, Liu Y, Paredes S, Villanova
L, Brown K, Qiu X, Nabavi N, Mohrin M, Wojnoonski K, et al: SIRT7
represses Myc activity to suppress ER stress and prevent fatty
liver disease. Cell Rep. 5:654–665. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kiran S, Oddi V and Ramakrishna G: Sirtuin
7 promotes cellular survival following genomic stress by
attenuation of DNA damage, SAPK activation and p53 response. Exp
Cell Res. 331:123–141. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vakhrusheva O, Smolka C, Gajawada P,
Kostin S, Boettger T, Kubin T, Braun T and Bober E: Sirt7 increases
stress resistance of cardiomyocytes and prevents apoptosis and
inflammatory cardiomyopathy in mice. Circ Res. 102:703–710. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ryu D, Jo YS, Lo Sasso G, Stein S, Zhang
H, Perino A, Lee JU, Zeviani M, Romand R, Hottiger MO, et al: A
SIRT7-dependent acetylation switch of GABPβ1 controls mitochondrial
function. Cell Metab. 20:856–869. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yu H, Ye W, Wu J, Meng X, Liu RY, Ying X,
Zhou Y, Wang H, Pan C and Huang W: Overexpression of sirt7 exhibits
oncogenic property and serves as a prognostic factor in colorectal
cancer. Clin Cancer Res. 20:3434–3445. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Paredes S, Villanova L and Chua KF:
Molecular pathways: Emerging roles of mammalian Sirtuin SIRT7 in
cancer. Clin Cancer Res. 20:1741–1746. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ashraf N, Zino S, Macintyre A, Kingsmore
D, Payne AP, George WD and Shiels PG: Altered sirtuin expression is
associated with node-positive breast cancer. Br J Cancer.
95:1056–1061. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Geng Q, Peng H, Chen F, Luo R and Li R:
High expression of Sirt7 served as a predictor of adverse outcome
in breast cancer. Int J Clin Exp Pathol. 8:1938–1945.
2015.PubMed/NCBI
|
|
37
|
Li L, Han LY, Yu M, Zhou Q, Xu JC and Li
P: Pituitary tumor-transforming gene 1 enhances metastases of
cervical cancer cells through miR-3666-regulated ZEB1. Tumour Biol.
2015.
|
|
38
|
Wang G, Cai C and Chen L: MicroRNA-3666
regulates thyroid carcinoma cell proliferation via MET. Cell
Physiol Biochem. 38:1030–1039. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shi H, Ji Y, Zhang D, Liu Y and Fang P:
MicroRNA-3666-induced suppression of SIRT7 inhibits the growth of
non-small cell lung cancer cells. Oncol Rep. 36:3051–3057. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Coronnello C and Benos PV: ComiR:
Combinatorial microRNA target prediction tool. Nucleic Acids Res.
41:W159–W164. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tao WY, Wang CY, Sun YH, Su YH, Pang D and
Zhang GQ: MicroRNA-34c suppresses breast cancer migration and
invasion by targeting GIT1. J Cancer. 7:1653–1662. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hua K, Jin J, Zhang H, Zhao B, Wu C, Xu H
and Fang L: MicroRNA-7 inhibits proliferation, migration and
invasion of thyroid papillary cancer cells via targeting CKS2. Int
J Oncol. 49:1531–1540. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pan Y, Jiao G, Wang C, Yang J and Yang W:
MicroRNA-421 inhibits breast cancer metastasis by targeting
metastasis associated 1. Biomed Pharmacother. 83:1398–1406. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Guo L, Yuan J, Xie N, Wu H, Chen W, Song S
and Wang X: miRNA-411 acts as a potential tumor suppressor miRNA
via the downregulation of specificity protein 1 in breast cancer.
Mol Med Rep. 14:2975–2982. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Barber MF, Michishita-Kioi E, Xi Y,
Tasselli L, Kioi M, Moqtaderi Z, Tennen RI, Paredes S, Young NL,
Chen K, et al: SIRT7 links H3K18 deacetylation to maintenance of
oncogenic transformation. Nature. 487:114–118. 2012.PubMed/NCBI
|
|
47
|
Singh S, Kumar PU, Thakur S, Kiran S, Sen
B, Sharma S, Rao VV, Poongothai AR and Ramakrishna G:
Expression/localization patterns of sirtuins (SIRT1, SIRT2 and
SIRT7) during progression of cervical cancer and effects of sirtuin
inhibitors on growth of cervical cancer cells. Tumour Biol.
36:6159–6171. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhang S, Chen P, Huang Z, Hu X, Chen M, Hu
S, Hu Y and Cai T: Sirt7 promotes gastric cancer growth and
inhibits apoptosis by epigenetically inhibiting miR-34a. Sci Rep.
5:97872015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang HL, Lu RQ, Xie SH, Zheng H, Wen XM,
Gao X and Guo L: SIRT7 exhibits oncogenic potential in human
ovarian cancer cells. Asian Pac J Cancer Prev. 16:3573–3577. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Aljada A, Saleh AM, Alkathiri M, Shamsa
HB, Al-Bawab A and Nasr A: Altered Sirtuin 7 expression is
associated with early stage breast cancer. Breast Cancer (Auckl).
9:3–8. 2015.PubMed/NCBI
|
|
51
|
Cioffi M, Vallespinos-Serrano M, Trabulo
SM, Fernandez-Marcos PJ, Firment AN, Vazquez BN, Vieira CR, Mulero
F, Camara JA, Cronin UP, et al: MiR-93 controls adiposity via
inhibition of Sirt7 and Tbx3. Cell Rep. 12:1594–1605. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kurylowicz A, Owczarz M, Polosak J, Jonas
MI, Lisik W, Jonas M, Chmura A and Puzianowska-Kuznicka M: SIRT1
and SIRT7 expression in adipose tissues of obese and normal-weight
individuals is regulated by microRNAs but not by methylation
status. Int J Obes (Lond). 40:1635–1642. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Gu S, Ran S, Liu B and Liang J: miR-152
induces human dental pulp stem cell senescence by inhibiting SIRT7
expression. FEBS Lett. 590:1123–1131. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zhao L and Wang W: miR-125b suppresses the
proliferation of hepatocellular carcinoma cells by targeting
Sirtuin7. Int J Clin Exp Med. 8:18469–18475. 2015.PubMed/NCBI
|
|
55
|
Han Y, Liu Y, Zhang H, Wang T, Diao R,
Jiang Z, Gui Y and Cai Z: Hsa-miR-125b suppresses bladder cancer
development by down-regulating oncogene SIRT7 and oncogenic long
non-coding RNA MALAT1. FEBS Lett. 587:3875–3882. 2013. View Article : Google Scholar : PubMed/NCBI
|
